EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study

Monica Lo, Anish K Amin iD, Marcin Kowalski, Anne Kroman, Dilip Mathew, Valay Parikh, Stanislav Weiner, Jennifer M Joseph, Leonard Ganz, Mohammed Mortada, AVEIR DR Study Group/Consortium

Journal of Cardiovascular Electrophysiology · 2026

DOI: 10.1111/jce.70255 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Monica Lo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Arkansas Heart Hospital, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Pacemaker, Artificial, Cardiac Pacing, Artificial, Arrhythmias, Cardiac. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

AVEIR DR, an industry‐first dual‐chamber leadless pacemaker (LP), provides continuous atrioventricular synchrony through implant‐to‐implant (i2i) communication between atrial and ventricular LP devices. It is important to evaluate the early real‐world comparative safety of AVEIR DR LP.

Objective

To compare complications and mortality between AVEIR DR LP and dual‐chamber transvenous pacemakers (TP).

Methods

De novo LP and TP patients were identified in Medicare Fee‐for‐Service claims (October 2023 and December 2024). Outcomes were 30‐day and 6‐month complications, reinterventions, heart failure hospitalizations, and all‐cause mortality. Comparisons were adjusted for demographics, comorbidities, and hospital encounter characteristics.

Results

Compared to TP ( N = 77 422, age = 79.6 ± 7.5), LP patients ( N = 759, age = 78.5 ± 7.8) had a higher comorbidity index, more dialysis dependence, end‐stage renal disease, and atrial fibrillation. Adjusted 30‐day overall complications (7.9% vs. 9.2%; odds ratio [OR] 0.85, p = 0.36) and mortality (1.8% vs. 1.5%; hazard ratio [HR] 1.21, p = 0.47) were comparable, while device‐related complications (2.0% vs. 3.9%; OR 0.50, p < 0.01) were lower with LP. Adjusted 6‐month overall complications (4.1% vs. 6.9%; HR 0.59, p < 0.01), device‐related complications (2.8% vs. 5.9%; HR 0.48, p < 0.01), and device reinterventions (2.1% vs. 4.3%; HR 0.49, p < 0.01) were reduced with LP, with no difference in mortality (6.6% vs. 5.6%; HR 1.18, p = 0.43) and heart failure hospitalizations (3.8% vs. 4.1%; HR 0.91, p = 0.65).

Conclusion

Despite a higher comorbidity burden, AVEIR DR LP had significantly fewer device‐related complications, overall 6‐month complications, and device reinterventions compared to TP, with similar overall 30‐day complications, mortality, and heart failure hospitalizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pacemaker, ArtificialCardiac Pacing, ArtificialArrhythmias, CardiacHumansFemaleRisk FactorsTreatment OutcomeTime FactorsUnited StatesMaleAgedAged, 80 and overRisk AssessmentProsthesis DesignDatabases, FactualRetrospective StudiesHeart Rate

Stichwörter der Autor:innen

AVEIR DRleadless pacemakersoutcomesreinterventionssafetytransvenous pacemakers

Autor:innen und Institutionen

  • Arkansas Heart Hospital, Little Rock, Arkansas, USA.
  • OhioHealth Heart and Vascular Physicians, Columbus, Ohio, USA.
  • Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
  • Staten Island University Hospital, Northwell Health, Staten Island, New York, USA.
  • Medical University of South Carolina, Charleston, South Carolina, USA.
  • Sarasota Memorial Hospital, Sarasota, Florida, USA.

ORCID-Profile: Anish K Amin

Förderung

  • Abbott Laboratories

Zitieren

APA

Lo, M., Amin, A. K., Kowalski, M., Kroman, A., Mathew, D., Parikh, V., Weiner, S., Joseph, J. M., Ganz, L., Mortada, M., & AVEIR DR Study Group/Consortium (2026). Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70255

Vancouver

Lo M, Amin AK, Kowalski M, Kroman A, Mathew D, Parikh V, et al. Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70255

BibTeX
@article{Lo2026,
  author = {Lo, Monica and Amin, Anish K and Kowalski, Marcin and Kroman, Anne and Mathew, Dilip and Parikh, Valay and Weiner, Stanislav and Joseph, Jennifer M and Ganz, Leonard and Mortada, Mohammed and AVEIR DR Study Group/Consortium, AVEIR DR Study Group/Consortium},
  title = {Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  doi = {10.1111/jce.70255}
}
Kostenlos starten →